| Protocol | Description | Details |
| AMC-048 | Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt’s and Atypical Burkitt’s Lymphoma.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Chemotherapy: Systemic
| Randomized: No
Principal Investigator(s):
Anil Tulpule
Staff Members:
Nancy Berman
|
| AMC-053 | Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined with (R)ICE in Subjects with EBV and/or HHV-8 Positive Relapsed/ Refractory AIDS-Associated Non-Hodgkin’s Lymphoma.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Chemotherapy: Systemic
Immunomodulator
| Randomized: No
Principal Investigator(s):
Anil Tulpule
Staff Members:
Nancy Berman
Christine Duran
|
| AMC-059 | A Phase I/II Trial of PTC299 in Patients with HIV-Related Kaposi's Sarcoma.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Anti-Angiogenesis
| Randomized: No
Principal Investigator(s):
Anil Tulpule
Staff Members:
Nancy Berman
|
